南京境奥生物医药科技

Nanjing Jing'ao Biomedical Technology is a China-based biotechnology company specializing in the discovery and development of innovative small molecule drugs using targeted protein degradation (TPD) technologies. Established in 2021 and headquartered in the Nanjing Jiangbei New Area, the company leverages its proprietary PROTAC and molecular glue platforms to address proteins previously considered undruggable. Its primary therapeutic focus is on oncology and autoimmune diseases, aiming to provide next-generation solutions for refractory conditions. The company is led by industry veterans with significant experience in medicinal chemistry and drug discovery from major pharmaceutical firms. Nanjing Jing'ao is currently advancing a pipeline of early-stage programs through pre-clinical development.